Graciela N Gómez1, Nicolás Pérez2, Andrea Braillard Poccard3, Ramiro A Gómez3, Ana C Costi4, Mercedes A García4, Malena Viola5, Alejandro Benitez5, Mariana M Aciar6, María Crespo Espíndola6, Demelza Yucra7, Micaela A Cosatti8, Cecilia Pisoni8, Dafne Capelusnik9, María N Lojo10, Belen I Barrios11, Mariano Rivero12, Boris Kisluk13, Amelia Granel14. 1. Department of Immunology, Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires University, Autonomous City of Buenos Aires, 3150 Combatientes de Malvinas Ave, 1431, PC, Argentina. gragomez@live.com.ar. 2. Department of Immunology, Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires University, Autonomous City of Buenos Aires, 3150 Combatientes de Malvinas Ave, 1431, PC, Argentina. 3. Department of Rheumatology, Hospital de Clínicas, José de San Martín, Buenos Aires University, Autonomous City of Buenos Aires, Argentina. 4. Department of Rheumatology, Province of Buenos Aires, H.I.G.A San Martín, La Plata City, Argentina. 5. Department of Rheumatology, Hospital General de Agudos Dr. Cosme Argerich, Autonomous City of Buenos Aires, Argentina. 6. Department of Rheumatology, Hospital Nuestro Señor del Milagro, Salta City, Province of Salta, Argentina. 7. Department of Rheumatology, Sanatorio Güemes, Autonomous City of Buenos Aires, Argentina. 8. Department of Rheumatology, CEMIC, Autonomous City of Buenos Aires, Argentina. 9. Department of Rheumatology, Instituto de Rehabilitación Psicofsica (IREP), Autonomous City of Buenos Aires, Argentina. 10. Department of Rheumatology, Hospital Rossi, La Plata City, Province of Buenos Aires, Argentina. 11. Department of Rheumatology, Hospital Enrique Tornú, Autonomous City of Buenos Aires, Argentina. 12. Department of Rheumatology, British Hospital, Autonomous City of Buenos Aires, Argentina. 13. Department of Rheumatology, Hospital Eva Perón, Granadero Baigorria City, Province of Santa Fe, Argentina. 14. Department of Rheumatology, Hospital San Roque, La Plata City, Province of Buenos Aires, Argentina.
Abstract
INTRODUCTION/ OBJECTIVES: To describe clinical features in patients with inflammatory myopathies (IMs) from the Argentine Registry of Inflammatory Myopathies, and their relationship with myositis-specific antibodies (MSAs). METHODS: This cross-sectional study included 360 adult patients with dermatomyositis (DM), polymyositis (PM), and inclusion body myositis. Demographics, clinical, and serological characteristics were retrospectively recorded (2016-2019). MSAs were determined by immunoblotting. Patients who were positive for anti-Jo-1, Mi-2, and MDA5 were compared against a group of patients, taken as reference group, who were negative for all MSAs. RESULTS: Women 72%, median age at diagnosis was 47.3 years (18-82). The most frequent subtypes were DM (43.9%) followed by PM (30%).The most frequent MSAs were anti-Jo-1 (51/317), 16.1%; MDA5 (12/111), 10.8%, and Mi-2 (23/226), 10.2%. Anti-Jo-1 was associated (p < 0.05) with a higher frequency of chronic disease course, interstitial lung disease (ILD), arthritis, and mechanic's hands. Anti-Mi-2 was found in patients who had higher frequency of skin manifestations and higher CK values (p < 0.001). Patients with anti-MDA5 had normal or low CK levels. Anti-MDA5 was associated (p < 0.05) with skin manifestations, arthritis, and ILD. The rest of MSAs had frequencies lower than 8%. Anti-TIF1ϒ was found in eight DM patients and one had cancer. Anti-SRP was found in seven patients who had PM and elevated CK. CONCLUSION: Anti-Jo-1 was the most frequent MSA, and was associated with ILD; MDA5 was associated with CADM and ILD, and Mi-2, with classical DM. Despite the different prevalence with respect to other cohorts, the clinical characteristics for each MSA group were similar to the data reported in other studies. Key Points • This study describes the prevalence of MSAs in the Argentine Registry of IMs. • Anti-Jo-1 and anti-MDA5 were associated with ILD. • Anti-Mi-2 was the third most frequent MSA, associated with classical DM.
INTRODUCTION/ OBJECTIVES: To describe clinical features in patients with inflammatory myopathies (IMs) from the Argentine Registry of Inflammatory Myopathies, and their relationship with myositis-specific antibodies (MSAs). METHODS: This cross-sectional study included 360 adult patients with dermatomyositis (DM), polymyositis (PM), and inclusion body myositis. Demographics, clinical, and serological characteristics were retrospectively recorded (2016-2019). MSAs were determined by immunoblotting. Patients who were positive for anti-Jo-1, Mi-2, and MDA5 were compared against a group of patients, taken as reference group, who were negative for all MSAs. RESULTS:Women 72%, median age at diagnosis was 47.3 years (18-82). The most frequent subtypes were DM (43.9%) followed by PM (30%).The most frequent MSAs were anti-Jo-1 (51/317), 16.1%; MDA5 (12/111), 10.8%, and Mi-2 (23/226), 10.2%. Anti-Jo-1 was associated (p < 0.05) with a higher frequency of chronic disease course, interstitial lung disease (ILD), arthritis, and mechanic's hands. Anti-Mi-2 was found in patients who had higher frequency of skin manifestations and higher CK values (p < 0.001). Patients with anti-MDA5 had normal or low CK levels. Anti-MDA5 was associated (p < 0.05) with skin manifestations, arthritis, and ILD. The rest of MSAs had frequencies lower than 8%. Anti-TIF1ϒ was found in eight DMpatients and one had cancer. Anti-SRP was found in seven patients who had PM and elevated CK. CONCLUSION: Anti-Jo-1 was the most frequent MSA, and was associated with ILD; MDA5 was associated with CADM and ILD, and Mi-2, with classical DM. Despite the different prevalence with respect to other cohorts, the clinical characteristics for each MSA group were similar to the data reported in other studies. Key Points • This study describes the prevalence of MSAs in the Argentine Registry of IMs. • Anti-Jo-1 and anti-MDA5 were associated with ILD. • Anti-Mi-2 was the third most frequent MSA, associated with classical DM.
Authors: Luis Fernando Valladales-Restrepo; Ana Camila Delgado-Araujo; Brayan Stiven Aristizábal-Carmona; Lina María Saldarriaga-Rivera; Jorge Enrique Machado-Alba Journal: Int J Rheumatol Date: 2022-07-05
Authors: Andrés Hormaza-Jaramillo; Vanessa Bedoya-Joaqui; Germán Puerta-Sarmiento; Mario Bautista; Lady J Rios-Serna; Tatiana Delgado-Mora; Ivana Nieto-Aristizábal; Ingrid Ruiz-Ordoñez Journal: Front Med (Lausanne) Date: 2022-08-15